References
- Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol.8, 458–466 (2008).
- Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu. Rev. Immunol.28, 573–621 (2010).
- Farraye FA, Odze RD, Eaden J et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology138, 738–745 (2010).
- Vermeire S, Vermeulen N, Van Assche G et al. (Auto)antibodies in inflammatory bowel diseases. Gastroenterol. Clin. N. Am.37, 429–438 (2008).
- Sonu I, Lin MV, Blonski W et al. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol. Clin. N. Am.39, 559–599 (2010).
- Vikingsson S, Carlsson B, Almer SH et al. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther. Drug Monit.31(3), 345–350 (2009).
- Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med.330, 1841–1845 (1994).
- Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s disease cA2 study group. N. Engl. J. Med.337, 1029–1035 (1997).
- Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117, 244–279 (2008).
- Clark M, Colombel JF, Feagan BC et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology133, 312–339 (2007).
- Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol.106, 644–659 (2011).
- Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol. Clin. N. Am.35, 757–773 (2006).
- Kotlyar DS, Osterman MT, Diamond RH et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol.9(1), 36–41.e1 (2011).
- D’Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet371, 660–667 (2008).
- Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med.362, 1383–1395 (2010).
- Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology142(1), 63–70 (2012).
- Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353, 2462–2476 (2005).
- Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut60, 780–787 (2011).
- Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology132, 1672–1683 (2007).
- Feagan BG, Greenberg GR, Wild G et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin. Gastroenterol. Hepatol.6, 1370–1377 (2008).